Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Anna Bareschino

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Current Pharmaceutical Design|February 12, 2013
New molecular targets in the treatment of NSCLCClorinda Schettino, Maria Anna Bareschino, Paola Claudia Sacco, et al.
Reviews on Recent Clinical Trials|September 28, 2010
Factors driving the choice of the best second-line treatment of advanced NSCLCPaolo Maione, Antonio Rossi, Maria Anna Bareschino, et al.
The Oncologist|February 5, 2009
Potential treatment options after first-line chemotherapy for advanced NSCLC: maintenance treatment or early second-line?Cesare Gridelli, Paolo Maione, Antonio Rossi, et al.
Therapeutic Advances in Medical Oncology|July 27, 2011
Treating advanced non-small cell lung cancer in the elderlyPaolo Maione, Antonio Rossi, Paola Claudia Sacco, et al.
Clinical Lung Cancer|November 11, 2010
The role of maintenance treatment in advanced non-small-cell lung cancer: reality or early second line?Cesare Gridelli, Antonio Rossi, Paolo Maione, et al.
Anticancer Research|June 10, 2010
Erlotinib in the treatment of non-small cell lung cancer: current status and future developmentsCesare Gridelli, Paolo Maione, Maria Anna Bareschino, et al.
Expert Review of Vaccines|June 23, 2011
Non-small-cell lung carcinoma vaccines in clinical trialsAntonio Rossi, Paolo Maione, Clorinda Schettino, et al.
Clinical Advances in Hematology & Oncology : H&O|June 21, 2011
Non-small cell lung cancer therapy in the elderlyCesare Gridelli, Antonio Rossi, Paolo Maione, et al.
Therapeutic Advances in Medical Oncology|July 27, 2011
The potential role of bevacizumab in early stages and locally advanced non-small cell lung cancerClorinda Schettino, Maria Anna Bareschino, Antonio Rossi, et al.
Current Pharmaceutical Design|August 10, 2012
The c-Met inhibitors: a new class of drugs in the battle against advanced nonsmall-cell lung cancerAssunta Sgambato, Francesca Casaluce, Paolo Maione, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Current Pharmaceutical Design|February 12, 2013
New molecular targets in the treatment of NSCLCClorinda Schettino, Maria Anna Bareschino, Paola Claudia Sacco, et al.
Reviews on Recent Clinical Trials|September 28, 2010
Factors driving the choice of the best second-line treatment of advanced NSCLCPaolo Maione, Antonio Rossi, Maria Anna Bareschino, et al.
The Oncologist|February 5, 2009
Potential treatment options after first-line chemotherapy for advanced NSCLC: maintenance treatment or early second-line?Cesare Gridelli, Paolo Maione, Antonio Rossi, et al.
Therapeutic Advances in Medical Oncology|July 27, 2011
Treating advanced non-small cell lung cancer in the elderlyPaolo Maione, Antonio Rossi, Paola Claudia Sacco, et al.
Clinical Lung Cancer|November 11, 2010
The role of maintenance treatment in advanced non-small-cell lung cancer: reality or early second line?Cesare Gridelli, Antonio Rossi, Paolo Maione, et al.
Anticancer Research|June 10, 2010
Erlotinib in the treatment of non-small cell lung cancer: current status and future developmentsCesare Gridelli, Paolo Maione, Maria Anna Bareschino, et al.
Expert Review of Vaccines|June 23, 2011
Non-small-cell lung carcinoma vaccines in clinical trialsAntonio Rossi, Paolo Maione, Clorinda Schettino, et al.
Clinical Advances in Hematology & Oncology : H&O|June 21, 2011
Non-small cell lung cancer therapy in the elderlyCesare Gridelli, Antonio Rossi, Paolo Maione, et al.
Therapeutic Advances in Medical Oncology|July 27, 2011
The potential role of bevacizumab in early stages and locally advanced non-small cell lung cancerClorinda Schettino, Maria Anna Bareschino, Antonio Rossi, et al.
Current Pharmaceutical Design|August 10, 2012
The c-Met inhibitors: a new class of drugs in the battle against advanced nonsmall-cell lung cancerAssunta Sgambato, Francesca Casaluce, Paolo Maione, et al.
Pageof 3